Loading...
XWAR
URT
Market cap19mUSD
Jul 29, Last price  
52.40PLN
1D
0.00%
1Q
-37.62%
IPO
-46.53%
Name

Urteste SA

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
-100.00%
0003,0000
Net income
-6m
L+37.59%
000-4,059,999-5,586,000
CFO
-5m
L+40.31%
000-3,793,000-5,322,000

Profile

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland.
IPO date
Oct 27, 2021
Employees
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
3
 
Cost of revenue
6,034
2,879
Unusual Expense (Income)
NOPBT
(6,034)
(2,876)
NOPBT Margin
Operating Taxes
162
(1)
Tax Rate
NOPAT
(6,196)
(2,876)
Net income
(5,586)
37.59%
(4,060)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
27,708
BB yield
-19.66%
Debt
Debt current
315
124
Long-term debt
939
946
Deferred revenue
Other long-term liabilities
Net debt
(23,396)
(2,384)
Cash flow
Cash from operating activities
(5,322)
(3,793)
CAPEX
(1,743)
(1,193)
Cash from investing activities
(24,400)
(1,193)
Cash from financing activities
27,427
(113)
FCF
(7,301)
(4,108)
Balance
Cash
24,650
3,434
Long term investments
20
Excess cash
24,650
3,454
Stockholders' equity
(6,432)
(4,932)
Invested Capital
34,802
11,137
ROIC
ROCE
EV
Common stock shares outstanding
1,293
1,135
Price
109.00
37.97%
79.00
-17.62%
Market cap
140,943
57.16%
89,679
-11.11%
EV
117,547
87,295
EBITDA
(5,258)
(2,439)
EV/EBITDA
Interest
570
51
Interest/NOPBT